Sigyn Therapeutics (SIGY) Other Working Capital Changes (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Other Working Capital Changes of -$1300.0 for Q3 2025, up 65.76% sequentially from -$3797.0 in Q2 2025, and down 111.22% YoY from $11588.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Other Working Capital Changes (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Other Working Capital Changes for 8 years, with the latest figure at -$1300.0 in Q3 2025.
- Quarterly Other Working Capital Changes fell 111.22% year-over-year to -$1300.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$54217.0 (down 164393.94% YoY) and the FY2024 annual result came in at -$47273.0, down 206.4% from the prior year.
- Other Working Capital Changes rose to -$1300.0 in Q3 2025 per SIGY's latest filing, from -$3797.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $35461.0 in Q2 2022 and troughed at -$45220.0 in Q4 2024.
- A 5-year average of -$1603.9 and a median of -$875.0 in 2023 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes slumped 29202.16% in 2022, then jumped 1424.34% in 2024.
- Over 5 years, Other Working Capital Changes stood at -$25434.0 in 2021, then surged by 118.43% to $4688.0 in 2022, then sank by 55.5% to $2086.0 in 2023, then sank by 2267.79% to -$45220.0 in 2024, then surged by 97.13% to -$1300.0 in 2025.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$1300.0, -$3797.0, and -$3900.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,300.00 |
| Sep 30, 2025 | -1,300.00 |
| Sep 30, 2025 | -1,300.00 |
| Jun 30, 2025 | -3,797.00 |
| Jun 30, 2025 | -3,797.00 |
| Jun 30, 2025 | -3,797.00 |
| Mar 31, 2025 | -3,900.00 |
| Mar 31, 2025 | -3,900.00 |
| Mar 31, 2025 | -3,900.00 |
| Dec 31, 2024 | -45,220.00 |
| Dec 31, 2024 | -45,220.00 |
| Dec 31, 2024 | -45,220.00 |
| Sep 30, 2024 | 11,588.00 |
| Sep 30, 2024 | 11,588.00 |
| Sep 30, 2024 | 11,588.00 |
| Jun 30, 2024 | -8,858.00 |
| Jun 30, 2024 | -8,858.00 |
| Jun 30, 2024 | -8,858.00 |
| Mar 31, 2024 | -4,783.00 |
| Mar 31, 2024 | -4,783.00 |